EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy

Teppei Hagino iD, Akihiko Uchiyama, Marina Onda, Keiji Kosaka, Takeshi Araki, Sei-Ichiro Motegi, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Dermatitis® · 2026

DOI: 10.1089/derm.2025.0045 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Dermatitis®, 2026. Verfasst von Teppei Hagino und 8 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The data are limited on the real-world effectiveness of an anti-interleukin (IL)-13 monoclonal antibody lebrikizumab for atopic dermatitis (AD).

Objective

To evaluate the 24-week real-world effectiveness of lebrikizumab in Japanese patients with AD, stratified by the presence or absence of prior systemic therapy.

Methods

We conducted a multicenter, prospective study of 134 Japanese AD patients treated with lebrikizumab. We evaluated clinical outcomes throughout a 24-week period in patients with or without prior systemic therapy.

Results

Among lebrikizumab-treated patients, eczema area and severity index (EASI) and scores of patient-reported outcomes (peak pruritus numerical rating scale, sleep quality numerical rating scale, AD control tool, dermatology life quality index, and patient-oriented eczema measure) rapidly decreased until week 12, and these improvements persisted until week 24. At week 24, the achievement rates of EASI 75, EASI 90, and investigator’s global assessment 0/1 in systemic therapy-naïve patients were 75.6%, 58.5%, and 43.5%, respectively, which were higher than those in systemic therapy-experienced patients, 55.5%, 22.2%, and 26.9%, respectively. There were no serious treatment-emergent adverse events until week 24.

Conclusion

Lebrikizumab treatment provided favorable effectiveness and tolerability for AD in real-world practice, with slightly higher effectiveness in systemic therapy-naïve patients compared to therapy-experienced patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalDermatitis, AtopicAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultJapanProspective StudiesSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, Humanized

Substanzen

Antibodies, MonoclonallebrikizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino

Zitieren

APA

Hagino, T., Uchiyama, A., Onda, M., Kosaka, K., Araki, T., Motegi, S. I., Saeki, H., Fujimoto, E., & Kanda, N. (2026). 24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy. Dermatitis®. https://doi.org/10.1089/derm.2025.0045

Vancouver

Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi SI, et al. 24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy. Dermatitis®. 2026. doi:10.1089/derm.2025.0045

BibTeX
@article{Hagino2026,
  author = {Hagino, Teppei and Uchiyama, Akihiko and Onda, Marina and Kosaka, Keiji and Araki, Takeshi and Motegi, Sei-Ichiro and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy},
  journal = {Dermatitis®},
  year = {2026},
  doi = {10.1089/derm.2025.0045}
}
Kostenlos starten →